STOCK TITAN
  1. Home
  2. Sec-filings
  3. RMD
  4. [Form 4] RESMED INC Insider Trading Activity

ResMed (RMD) CEO sells 4,991 shares after exercising stock options

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and related share sale. On February 9, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of common shares.

That same day, he sold 4,991 ResMed common shares in market transactions at a weighted average price of $273.7801 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed common shares and held an additional 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, along with 44,921 stock options beneficially owned.

Positive

  • None.

Negative

  • None.
Insider Farrell Michael J.
Role Chairman and CEO
Sold 4,991 shs ($1.37M)
Type Security Shares Price Value
Exercise ResMed Common Stock Options 4,991 $0.00 --
Exercise ResMed Common Stock 4,991 $146.34 $730K
Sale ResMed Common Stock 4,991 $273.7801 $1.37M
holding ResMed Common Stock -- -- --
Holdings After Transaction: ResMed Common Stock Options — 44,921 shares (Direct); ResMed Common Stock — 471,214 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)
Footnotes (1)
  1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $270.25 - $276.35. The price reported above reflects the weighted average sale price. Represents date options first become exercisable. Options vest 1/3 per year.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farrell Michael J.
(Last) (First) (Middle)
RESMED INC.
9001 SPECTRUM CENTER BLVD
(Street)
SAN DIEGO CA 92123
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman and CEO
3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
ResMed Common Stock 02/09/2026 M(1) 4,991 A $146.34 471,214 D
ResMed Common Stock 02/09/2026 S(1) 4,991 D $273.7801(2) 466,223 D
ResMed Common Stock 2,090 I Lisette and Michael Farrell Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
ResMed Common Stock Options $146.34 02/09/2026 M(1) 4,991 11/11/2020(3) 11/21/2026 ResMed Common Stock 4,991 $0 44,921 D
Explanation of Responses:
1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. This transaction was executed in multiple trades at prices ranging from $270.25 - $276.35. The price reported above reflects the weighted average sale price.
3. Represents date options first become exercisable. Options vest 1/3 per year.
/s/ Michael J. Farrell, Chairman and CEO 02/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ResMed (RMD) CEO Michael Farrell report?

Michael J. Farrell reported exercising 4,991 ResMed common stock options and selling 4,991 common shares. The exercise price was $146.34 per share, and the sale used a weighted average price of $273.7801 per share on February 9, 2026, under a Rule 10b5-1 plan.

At what prices did Michael Farrell exercise and sell ResMed (RMD) shares?

He exercised 4,991 ResMed common stock options at $146.34 per share and sold 4,991 common shares at a weighted average price of $273.7801. The sales occurred in multiple trades within a $270.25 to $276.35 range on February 9, 2026.

How many ResMed (RMD) shares does CEO Michael Farrell own after this Form 4?

After the reported transactions, Michael J. Farrell directly owned 466,223 ResMed common shares. He also had indirect ownership of 2,090 shares through the Lisette and Michael Farrell Family Trust and beneficially owned 44,921 ResMed common stock options following the February 9, 2026 activity.

Was the ResMed (RMD) CEO’s share sale part of a Rule 10b5-1 plan?

Yes. The Form 4 states the sale transaction was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Such plans pre-schedule trades, allowing insiders to systematically sell shares according to predetermined instructions over time.

What derivative securities are involved in Michael Farrell’s ResMed (RMD) Form 4?

The filing shows ResMed common stock options with an exercise price of $146.34 per share. On February 9, 2026, 4,991 options were exercised into common shares, leaving 44,921 derivative securities beneficially owned, with options vesting one-third per year from the initial exercisable date.

How were Michael Farrell’s ResMed (RMD) share sales priced during the transaction?

The Form 4 notes the sale occurred in multiple trades between $270.25 and $276.35 per share. The reported transaction price of $273.7801 per share represents the weighted average sale price across all those individual trades executed on February 9, 2026.